NCT00515268View on ClinicalTrials.gov

Endotoxin Challenge Study For Healthy Men and Women

PHASE1CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

September 27, 2007

Primary Completion Date

April 23, 2008

Study Completion Date

April 23, 2008

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG

GSK256066

GSK256066 will be available as dry powder inhaler with dosing strengths of 12.5, 37.5, 50 micrograms per inhalation.

DRUG

Placebo

Subjects will receive placebo inhaler.

Trial Locations (1)

30625

GSK Investigational Site, Hanover

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY